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The prognostic value of the ANCA associated glomerulonephritis (ANCA GN) classification has 
been demonstrated in several cohorts with sclerotic class having the worst renal outcome.  
Relevant published data on factors predicting outcomes in sclerotic ANCA GN is limited. 
Methods: 
Sclerotic ANCA GN patients were recruited from 5 centers worldwide for this retrospective 
cohort study. We describe the clinical characteristics of this cohort and evaluate predictors of 
one-year GFR and ESRD.  Kidney function at 12 months as measured by MDRD eGFR was 
modeled by simple and multiple linear regression.  We used Cox proportional hazards 
regression modeling to evaluate ESRD-free survival.  
Results:  
Of the 50 patients, 92% were Caucasian and 60% male with a mean age of 61 years. 72% had 
renal limited disease and 82% were MPO ANCA positive. Kidney biopsies contained a median 
of 20 (IQR 15-34) glomeruli with 96% showing moderate to severe interstitial fibrosis.  96% of 
patients received immunosuppressive drug therapy and 16% received plasmapheresis. 
Treatment response was achieved in all but one patient. The median (IQR) eGFR at entry was 
14.5 (9-19) ml/min/1.73m2.  Over a median (IQR) follow up of 33.5 (17-82) months, 26 patients 
reached ESRD. Ten patients died with six of them occurring within the first year of diagnosis.  
The hazard of progression to ESRD was significantly higher in those with lower GFR at study 
entry (p=0.003) and with higher degree of tubular atrophy (p=0.043). 
Conclusions: 
Renal recovery is rare among sclerotic ANCA GN patients requiring dialysis at entry and 12% of 
patients died in the first year. Entry GFR and tubular atrophy were significant predictors of GFR 
at 12 months and renal survival in patients with sclerotic class ANCA GN. 
1. Introduction: 
The ANCA associated vasculitides (AAV) are systemic necrotizing vasculitides 
characterized by the presence of circulating anti-neutrophil cytoplasmic antibody (ANCA) in 
about 90% of patients.[1]   AAV include granulomatosis with polyangiitis (GPA), microscopic 
polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis and renal limited vasculitis.[2] 
ANCA-associated glomerulonephritis (ANCA GN) is present more than 50% of AAV patients at 
diagnosis and about 70-85% of these patients develop renal vasculitis during their disease 
course.[3]  Severe renal dysfunction portends a poor prognosis and causes end stage renal 
disease (ESRD) or death in 50% of patients at 5 years.[3, 4]  Recent advances in therapy have 
transformed AAV from a fatal disease to one with a relapsing course but substantial treatment 
related morbidity exists.  Data from the European vasculitis study group demonstrates that the 
mortality is highest in the first year with most of them being attributable to infection.[5]  
Prognosis is an important issue in renal vasculitis where both the disease and therapies may 
lead to significant morbidity and mortality. 
Several histopathologic studies have demonstrated that the combination of GFR at 
baseline and renal histology is a better predictor of renal outcome than GFR alone.[6-12] In 
2010, an international working group of renal pathologists proposed a new classification for 
ANCA GN based on glomerular pathology to assess its predictive value for renal survival and 
validated it using patient data.[13]  The classification system categorized ANCA GN into four 
classes based on glomerular pathology: focal, crescentic, mixed and sclerotic. Subsequent to 
this study, a number of validation studies in several cohorts in Europe, Asia and United States 
confirmed the predictive value of this classification for renal survival in focal and sclerotic class 
and mixed results in crescentic and mixed class.[14]  The sclerotic class ANCA GN had the 
worst short and long term renal survival. Following treatment, the one and five-year renal 
survival in these patients is about 50% suggesting that renal function can be stabilized with 
treatment in a significant number of patients. There is lack of data on prognostic markers to 
identify patients who progress to ESRD where immunosuppression is likely to cause more harm 
than benefits. This study aims to determine prognostic markers of renal outcome among 
patients with sclerotic class ANCA GN. 
 
2. Methods: 
The study patients were recruited from five centers worldwide (United States, the United 
Kingdom, the Czech Republic, Ireland and China). Patients were eligible for study entry if they 
had ANCA-associated GN clinically as well as biopsy-proven sclerotic class ANCA GN, defined 
as >50% of glomeruli on biopsy sample demonstrating global sclerosis.  Biochemical, clinical 
measurements and details of immunosuppressive therapy were recorded with time origin being 
the time of kidney biopsy. The number of normal glomeruli, glomeruli with cellular crescents and 
fibrocellular crescents were recorded for each biopsy by review of paper reports and slides. The 
degree of interstitial fibrosis and tubular atrophy was graded mild (<25%), moderate (25 to 50%) 
or severe (>50%) depending on extent of involvement.  Patients with missing data regarding 
diagnosis of ESRD, estimated glomerular filtration rate (eGFR), both at baseline and at 12 
months, were excluded from analysis. Treatment response was defined clinically by stabilization 
or improvement of serum creatinine with resolution of hematuria and absence of signs of extra-
renal vasculitis. Relapse was defined by biopsy proven pauci-immune GN or an increase in 
vasculitis activity requiring an increase in immunosuppressive drug therapy. The study was 
approved by Institutional review board at each center.  Notably, because there is no 
standardized treatment guidelines for sclerotic class ANCA vasculitis, patients observed in this 
study underwent a number of different immunosuppression regimens as will be explained in 
detail below.  The study outcomes were 12-month eGFR based on the equation derived by 
Levey and colleagues based on the Modification of Diet in Renal Disease (MDRD) Study and 
ESRD defined as need for initiation of renal replacement therapy in the form of dialysis or 
transplant.[15] Estimated GFR at 12 months was modeled as a function of various predictors 
using both simple and multiple linear regression.  The hazard of ESRD was modeled using Cox 
proportional hazards regression in both univariable and multivariable analyses.  The Breslow 
method was used for ties. The outcome of ESRD-free survival was further demonstrated with 
Kaplan-Meier survival curves.  The degree of tubular atrophy and interstitial fibrosis were 
categorized as mild, moderate, or severe on biopsy.  All analyses were run using Stata Version 
15 (Stata Corporation, College Station, TX). 
 
3. Results: 
Of the fifty patients who met the inclusion criteria, 92% were Caucasian and 60% were 
male with a median overall age at biopsy of 63.5 (IQR 50-73) years.  Eight patients (16%) were 
positive for PR3 and forty-one (82%) were positive for MPO.  The remaining patient was ANCA 
negative by serolgies but with a biopsy showing pauci-immune vasculitis with evidence of 
sclerosis. Thirty-six patients (72%) had renal limited AAV and the remaining patients had 
evidence of extra-renal disease. The median eGFR at entry was 14.5 (IQR 9-19) ml/min/1.73m2. 
Baseline characteristics can be found in Table 1. 
Kidney biopsies obtained a median of 20 (IQR 15-34) glomeruli, of which 23 specimens 
(46%) had some evidence of fibrocellular crescents, while 28 (56%) had some evidence of 
fibrous crescent formation.  Only two biopsies had less than ten glomeruli for analysis. The 
median percent sclerosed glomeruli in samples was 67 (IQR 59-75).  In total, 48 biopsy samples 
(96%) showed moderate to severe interstitial fibrosis (IF).  Only twenty patients (40%) had any 
normal-appearing glomeruli on biopsy, and of these, over half (12 patients) had only 1-2 normal 
glomeruli visualized.  32 specimens (64%) had at least one cellular crescent, while 11 (22%) 
had 3 or more.  Out of thirty-two patients with evidence of tubular atrophy on biopsy, two were 
classified as mild and thirteen showed moderate atrophy, while the majority (17) demonstrated 
severe atrophy. 
A total of forty-eight patients (96%) were treated with immunosuppressive medications. 
Eight patients also received plasmapheresis. Thirty-five patients (70%) received pulse 
intravenous (IV) methylprednisolone, while thirty-two (64%) received cyclophosphamide. Of the 
thirty-two patients treated with cyclophosphamide, twenty-four (75%) received IV 
cyclophosphamide while the remaining eight received the oral formulation.  Eleven (22%) 
patients received IV rituximab and four patients received both cyclophosphamide and rituximab 
(8%) (Table1).  Of the 48 patients treated with immunosuppressive therapy with or without 
plasmapheresis, one patient never achieved treatment response despite treatment with 
cyclophosphamide and rituximab.  Of the two patients who did not receive any 
immunosuppression, both had renal-limited disease and progressed to ESRD.   
Outcomes were observed in the clinical setting with follow-up times varying by center, 
but on average 2-3 months between visits.  Overall, treatment response was achieved in nearly 
all patients undergoing treatment (n=47/48, 98%), which occurred in the first 4-6 months of 
follow-up. Out of the forty-eight who received immunosuppression, thirty-four patients received 
maintenance immunosuppression. Of those patients who achieved initial treatment response, 
nine (18.3%) experienced relapse, five of which involved the kidney.  Ten patients died during 
follow up with 6 of them in the first year of diagnosis. Of the six early deaths, three were 
infection related, one patient died after complications of femoral neck fracture and the cause of 
death was unknown in two patients.  One of the six patients was HD-dependent at study entry. 
For our analysis, kidney function at 12 months was first modeled by simple linear 
regression, excluding those 6 patients who died within the first year from analysis 
(Supplemental Table 1).  In univariable analysis, entry eGFR was positively associated with 
eGFR at 12 months (β=1.16 mL/min/1.73m2; 95% CI: 0.816, 1.51).  The degree of tubular 
atrophy was also statistically significantly associated with 12-month GFR (β=-10.5 
mL/min/1.73m2; 95% CI: -18.4, -2.67). With regard to treatment, there was a statistically 
significant higher 12-month eGFR in patients who received rituximab (β=14.0 mL/min/1.73m2; 
95% CI 6.58, 21.5), while the use of cyclophosphamide was statistically significantly associated 
with a lower GFR at 12 months (β= -11.1 mL/min/1.73m2; 95% CI -18.6, -3.63).  Age and degree 
of interstitial fibrosis were not statistically significantly associated with eGFR at 12 months, 
though a higher degree of interstitial fibrosis approached clinical significance with a decline in 
GFR.  Further, there was no statistically significant association between 12-month eGFR and 
gender, ANCA type, or other pathologic features (percentage of normal glomeruli, percentage of 
cellular crescents).  In our multivariable model, further adjusted for use of rituximab and 
cyclophosphamide, both entry GFR and degree of tubular atrophy remained statistical 
significant (r2=0.722; Table 2). 
Among the thirty-eight patients not requiring hemodialysis (HD) at study entry, fifteen 
went on to develop ESRD (39.5%) compared to eleven out of the twelve patients on HD at study 
entry (91.7%) (Supplemental Figure 1).     All thirty-eight patients were treated with 
immunosuppression and even those who eventually progressed to ESRD showed some initial 
treatment response. In total, ten of the twelve patients who were HD dependent at study entry 
received at least some immunosuppression, of which only one had treatment response. The 
incidence rate of ESRD for those who were on HD at the time of diagnosis was 40.7/100 
person-months (95% CI: 22.7, 73.6).  In comparison, for the 38 patients who were not HD-
dependent at the start of diagnosis, the incidence rate of ESRD was 5.88/100 person-months 
(95% CI: 3.55, 9.76)  
ESRD-free, or renal, survival was modeled with Cox proportional hazards regression 
(Tables 3, Supplemental Table 2).   In univariable analysis, there was a statistically significantly 
increased hazard of progressing to ESRD with lower eGFR at study entry (1.11, 95% CI 1.04, 
1.19).    Similarly, dialysis-dependence at study entry was also associated with an increased 
hazard of ESRD (HR=11.1, 95% CI: 4.04, 30.7).  A higher degree of tubular atrophy was 
associated with progression to ESRD as well (HR=2.69, 95% CI: 1.03, 7.01).  In a multivariable 
model including both entry GFR and degree of tubular atrophy, entry-GFR remained statistically 
significantly associated, with a lower hazard of ESRD with higher GFR, while the risk of ESRD 
with increasing tubular atrophy was no longer statistically significant.  Tubular atrophy was 
classified as mild, moderate, or severe and modeled accordingly.  Renal survival was visually 
depicted using Kaplan-Meier graphs showing the differential progression to ESRD by these 
variables (Figures 1-2, Supplemental Figure 2).  For the purposes of the Kaplan-Meier graphs, 




 We report the results of the largest series of sclerotic class ANCA GN patients that 
aimed to ascertain predictors of renal outcome. In this study, baseline GFR and tubular atrophy 
are predictors of both one-year GFR and overall renal survival. The study demonstrates that 
renal recovery is very rare among patients who are dialysis dependent at entry.  
This study comprised on predominantly MPO ANCA positive patients. This might directly 
be related to the inclusion of only sclerotic class ANCA GN in this study and reflects high 
prevalence of chronic lesions in MPO ANCA patients seen in prior studies.[9, 16]  Entry GFR 
has been shown to be an independent predictor of renal outcome in multiple cohorts [4, 8, 9, 17-
19] and remains the best predictor in this study comprised of sclerotic class ANCA GN. In fact, 
the correlation of entry GFR with long term renal outcome is so strong that the prognostic 
significance of ANCA GN classification disappears when adjusted for entry GFR.[19]  
The prognostic value of the ANCA GN classification was strengthened by adding the 
percent normal glomeruli in the crescentic and mixed ANCA GN [20] or by adding percent 
crescent in mixed class.[19]. Among the histologic predictors of renal outcome, percent normal 
glomeruli has been demonstrated to predict renal function in previous studies. A correlation 
between percentage normal glomeruli and renal function has been demonstrated in previous 
studies.[6-9, 11, 12, 19]. In patients with crescentic and mixed type ANCA GN, the presence of 
>25% normal glomeruli was predictive of improved GFR. [20] The findings in this study are in 
contrast and this may be related to the overall chronicity score seen in our cohort. 
Cellular crescents have been shown to respond to immunosuppressive therapy and 
subsequent improvement in GFR.[9]  In mixed class ANCA GN, presence of less than 20% 
cellular crescents in the biopsy sample was associated with a lower one-year GFR by Tanna et 
al.  In his study, the presence of cellular crescents did not correlate with improved GFR. This 
may be related to the underlying severe chronic changes in sclerotic class ANCA GN.  
This study demonstrates that the degree of tubular atrophy correlated with long term 
renal outcome. Historically chronic tubulo-interstitial lesions have been identified as predictors of 
adverse renal outcome.[8, 9, 21, 22]  Adding interstitial fibrosis and tubular atrophy to enhance 
the predictive value of ANCA GN classification has yielded variable results. An association 
between higher degree of tubular atrophy and worse renal outcome was reported by Quintana 
et al.[19, 23]  In the Berden study and in Chinese cohort, there was no correlation of interstitial 
fibrosis and tubular atrophy with long term renal function.[13, 24]  
Patients with sclerotic class GN have adverse prognosis with persistently elevated risk of 
ESRD or death in multiple cohorts.[13, 14, 25] The one and five year renal survival in validation 
studies have ranged from 29 to 52% and 29 to 75%.[19, 23, 26]  Similar to these studies, we 
see poor renal and patient survival in our cohort.  It may be that in those patients with significant 
tubular atrophy, and sclerotic class disease, especially if they are dialysis-dependent on biopsy, 
that any treatment would prove fruitless.  Future studies are needed to evaluate the influence of 
treatment, particularly in those patients with significant kidney injury at the start of therapy.  
 We acknowledge that the study is subject to limitations inherent in a retrospective study. 
Although, the histo-pathological scoring was performed by experienced pathologists, inter-
observer variation was not assessed. There are insufficient data to explore the association of 
plasmapheresis and outcomes in sclerotic class ANCA GN, as well as too few observations for 
any significant adjustment for potential confounders.  Further, as only nine patients experienced 
relapse over the course of follow-up, there was not sufficient power to model this outcome in 
any meaningful fashion. The study was enriched with MPO ANCA patients and may not be 
generalizable to PR3 ANCA patients. 
 In conclusion, the study demonstrates that renal recovery is rare in patients requiring 
dialysis at entry despite standard immunosuppression in sclerotic ANCA GN patients. Baseline 
GFR and tubular atrophy remain as predictors of renal outcome. More information is needed on 
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